SPDR S&P Biotech

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Madrigal Pharmaceuticals Reports Q1 2026 Net Loss Widens to $94.39M Despite Strong Rezdiffra Revenue Amidst Uncertainty

Bank of America Analyst Maintains Buy Rating on Travere Therapeutics with $50 Target Price

Travere Therapeutics Completes $525 Million Convertible Note Issuance for Refinancing and Operations

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Travere Therapeutics Receives 'Modest Buy' Consensus Rating from Thirteen Analysts

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Travere Therapeutics issues convertible notes and repurchases existing convertible notes

Celldyne Announces New Data Release for MYQORZO® at the 2026 European Heart Failure Conference

Cytokinetics Announces Aficamten Superior to Metoprolol in Phase III Study

Madrigal's Rezdiffra Strong Sales, ZSP1601 Shows Potential in Anti-Fibrotic Therapy

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

Travere Therapeutics Insider Sells Shares, Raises Short-Term Sell Pressure Concerns

Cytokinetics Prices Expanded Public Offering, Expected to Raise $700 Million

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

LABU

SBIO

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

West Pharmaceutical

iShares US Medical Devices

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Arcadian Asset

S&P 500

BAYRY

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Pharma

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Barclays Remains a Buy on Bayer (0P6S)

ENTA

ARKG

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Ark Genomic Revolution ETF

VG Health

Enanta Pharma's RSV Bet And Immunology Ambitions

RLAY

Relay Therapeutics reported a 60% response rate in its Phase 2 trial of zovegalisib for PIK3CA-driven vascular anomalies, with significant lesion shrinkage and symptom improvement in evaluable patients. The interim safety profile supports chronic dosing, and expansion cohorts are now using lower-dose regimens for adults and adolescents, while pediatric dose-finding continues.

PUBT

Relay Therapeutics

Relay Therapeutics reports 60% response rate in Phase 2 zovegalisib vascular anomalies trial

BAYN

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Nasdaq

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

RHHBY

Genentech presented new clinical data for giredestrant, an oral breast cancer drug, ahead of the ASCO 2026 meeting. The Phase III lidERA study will assess benefits across pre- and post-menopausal patients, supporting an FDA submission. Results from the persevERA study, despite missing its main goal, show numerical improvement in endocrine-sensitive disease. Additional analyses from the evERA trial will extend evidence for giredestrant in advanced breast cancer. Early safety and efficacy data for a HER2-targeted therapy will also be presented.

Roche

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

GILD

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Gilead Sciences

Gilead Sciences, Inc.

Invesco Nasdaq Biotechnology ETF

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Wave Life Sciences announced positive results from the RestorAATion-2 trial, showing that WVE-006 effectively restores M-AAT levels and reduces Z-AAT levels. In the 200 mg biweekly cohort, M-AAT reached 64% of total, while Z-AAT decreased by 71%. The 400 mg monthly dosing also showed significant results. The treatment was well tolerated with no liver toxicities. The company anticipates FDA feedback on accelerated approval by mid-2026 and plans to present further data in H2 2026.

TradingView

Wave Life Sciences

Bioshares Biotech Clinical Trials Fd

Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

NBIX

SLNO

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

Neurocrine Biosciences

Soleno Therapeutics

Goldman Sachs

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

REGN

The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant milestone for patients. Meanwhile, the agency faces instability with leadership departures, raising concerns about regulatory consistency. Additionally, Regeneron has entered a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates using AI-driven drug discovery.

Pharmexec

Regeneron Pharma

AstraZeneca

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

IBRX

ImmunityBio has secured exclusive U.S. rights to the Tokyo-172 BCG strain through a supply agreement with Japan BCG Laboratory. The agreement allows ImmunityBio to develop, conduct clinical trials, and manage regulatory approvals for 10 years post-FDA approval, with no upfront payments required. After approval, ImmunityBio must purchase at least two batches annually. The deal also includes rights for certain ex-U.S. territories.

ImmunityBio

ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory

SPDR S&P Biotech(XBI.US)